The annual SXSW Festival in Austin, Texas, known for its intersection of technology, culture, and business, became the backdrop for a sharp critique of the burgeoning direct-to-consumer healthcare industry. On a sweltering afternoon with temperatures exceeding 95 degrees, Mark Cuban, the billionaire co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of eMed Population Health, took the stage to address the rapidly evolving landscape of weight loss medication. Their discussion centered on the rise of GLP-1 agonists—such as Ozempic, Wegovy, and Zepbound—and the business practices of the platforms currently dominating the retail distribution of these drugs.
During the panel, Yaccarino and Cuban specifically targeted companies that have capitalized on the pharmaceutical gold rush triggered by national shortages of branded GLP-1 medications. While Yaccarino initially hesitated to name the competitors, Cuban interjected to clarify the targets of their criticism. The exchange focused on companies whose names "start with R’s and H’s," a transparent reference to Ro and Hims & Hers, two of the largest players in the direct-to-consumer (DTC) telehealth space. The critique was not merely academic; it highlighted a fundamental divide in how the healthcare industry views the long-term management of chronic obesity.
The Critique of Direct-to-Consumer Models and "Churn"
The central point of contention raised by Yaccarino and Cuban was the sustainability and clinical oversight of DTC platforms. Yaccarino alleged that these companies suffer from exceptionally high "churn" rates—the frequency at which customers cancel their subscriptions or stop treatment. According to Yaccarino, some of these platforms experience churn rates exceeding 50% or 60%. She attributed this lack of retention to a deficit in clinical supervision, suggesting that patients are often left to navigate complex medication regimens with minimal professional guidance.
Cuban amplified this sentiment by characterizing these competitors as "mostly marketing companies." This characterization points to the massive advertising spends these firms have utilized to acquire customers. For instance, Hims & Hers notably ran a Super Bowl advertisement in 2025 focused on weight loss drugs, featuring their own branded medication packaging. Similarly, in early 2026, Ro launched a high-profile campaign featuring tennis legend Serena Williams. While Ro’s advertisement specified that the athlete was taking "FDA-approved GLP-1 drugs," Cuban and Yaccarino argued that the underlying business model remains focused on high-volume customer acquisition rather than long-term clinical outcomes.
Yaccarino described the operations of these competitors as "turning the knobs of the platforms" to ensure a steady influx of new users, comparing the healthcare delivery model to a digital marketing funnel. The implication of their critique is that without a "tight care community" and rigorous accountability, the clinical benefits of GLP-1 medications are likely to be lost as soon as the consumer stops paying the monthly subscription fee.
The eMed and Cost Plus Drugs Collaboration
The primary purpose of the SXSW appearance was to announce a strategic partnership between eMed Population Health and Cost Plus Drugs. This collaboration aims to provide a more structured, B2B-focused alternative to the retail DTC model. Under the new agreement, eMed’s employer customers will have their employees’ GLP-1 medication needs fulfilled through Cuban’s Cost Plus Drugs pharmacy.
Miami-based eMed has positioned itself as a digital health company specializing in at-home blood collection and managed GLP-1 weight loss programs. Unlike the retail-facing models criticized by the duo, eMed focuses on the employer-sponsored insurance market. Yaccarino contrasted the high churn of competitors with eMed’s reported 90% retention rate—representing the percentage of users who remain on their medication and within the program after one full year.
The eMed model relies heavily on biometric verification and frequent touchpoints. "The thing of why eMed is the leading B2B employer program is because you have to check in with us every week," Yaccarino explained during the panel. The process involves facial recognition technology and integrated smart scales to track patient progress in real-time. This data allows clinicians to monitor titration—the process of adjusting medication dosages—to minimize side effects and maximize efficacy. By making the user accountable through regular digital check-ins, eMed claims to foster the long-term adherence necessary for metabolic health.
The Economic Context: Shortages and Compounding
The tension in the GLP-1 market is a direct result of an unprecedented "gold rush" sparked by the efficacy of these drugs in treating obesity and type 2 diabetes. As demand surged in 2023 and 2024, manufacturers like Novo Nordisk and Eli Lilly struggled to keep up, leading to widespread shortages. This scarcity created a regulatory opening for compounding pharmacies.
Under federal law, when a drug is on the FDA’s official shortage list, compounding pharmacies are permitted to create "essentially a copy" of the medication to meet patient needs. This led to a proliferation of compounded semaglutide and tirzepatide, often sold at a fraction of the price of the branded versions. However, because compounded drugs do not undergo the same FDA pre-market approval process for safety and efficacy as branded drugs, some physicians and regulators have expressed concern.
Cuban and Yaccarino’s partnership seeks to navigate these concerns by focusing on the delivery of legitimate, branded medications at the lowest possible price point. Cuban’s Cost Plus Drugs has built its reputation on price transparency, bypassing traditional pharmacy benefit managers (PBMs) to sell drugs at a fixed 15% markup over wholesale costs. By applying this model to the GLP-1 space, the partnership aims to make branded medications more affordable for employers who are currently struggling with the massive budgetary impact of weight loss drug coverage.
A Chronology of Market Shifts and Legal Battles
The landscape of GLP-1 distribution has shifted rapidly over the last 24 months. To understand the current friction between these companies, one must look at the timeline of events leading up to the 2026 SXSW panel:
- June 2025: Novo Nordisk, the manufacturer of Wegovy and Ozempic, withdrew from a distribution collaboration with Hims & Hers.
- November 2025: The federal government, under the Trump administration, introduced the "TrumpRx" program. This initiative negotiated significantly lower prices for GLP-1 medications for Medicare beneficiaries and introduced coupon programs for the uninsured, putting downward pressure on market prices.
- February 2026: Novo Nordisk filed a lawsuit against Hims & Hers over the sale and marketing of compounded versions of its GLP-1 medications, alleging trademark infringement and safety concerns.
- March 2026: In a surprising reversal, Hims & Hers announced that Novo Nordisk had dropped the lawsuit. As part of a new agreement, Hims & Hers agreed to stop marketing compounded versions and instead became an official distributor for Novo’s branded Ozempic injections and Wegovy pills and injections.
This recent shift complicates the "marketing company" narrative presented by Cuban and Yaccarino. The fact that a major pharmaceutical manufacturer like Novo Nordisk chose to partner with a DTC platform—despite previous litigation—suggests that the massive customer bases built by these platforms have significant strategic value. It indicates a transition where DTC companies are evolving from "disruptors" using compounded alternatives into mainstream distribution channels for big pharma.
The Science of Adherence and Long-Term Implications
Beyond the business rivalry lies a critical medical concern: what happens when patients stop taking GLP-1s? Clinical studies have consistently shown that obesity is a chronic condition, and GLP-1 medications are not a "one-time fix." It is well-documented that patients who discontinue these drugs often regain a significant portion of the weight they lost within 12 to 18 months.
Yaccarino emphasized this point at SXSW, noting that if people discontinue the medication due to a lack of support or high costs, they lose the long-term cardiovascular and metabolic benefits of weight reduction. This "rebound effect" is the primary reason why eMed and Cost Plus Drugs are emphasizing a supervised, high-retention model. From an employer’s perspective, paying for a high-cost drug only to have the employee quit the program and regain the weight represents a poor return on investment.
The collaboration between Cuban and Yaccarino is an attempt to solve the "triple aim" of healthcare: improving the patient experience, improving population health, and reducing the per capita cost of care. By combining Cuban’s transparent pricing with eMed’s rigorous monitoring, the two hope to convince corporate America that weight loss programs can be both clinically effective and fiscally responsible.
Broader Impact on the Healthcare Industry
The debate on the SXSW stage reflects a broader struggle within the American healthcare system over the "retailization" of medicine. On one side are the DTC platforms that prioritize accessibility, ease of use, and digital-first experiences. On the other are models like eMed, which argue that chronic conditions require more intensive, "wrap-around" clinical services that go beyond a simple prescription.
As the price of GLP-1s continues to be a focal point of national policy—highlighted by the TrumpRx program and Medicare price negotiations—the competition to be the preferred provider for these medications will only intensify. The outcome will likely depend on which model can prove superior long-term health outcomes. If the 90% retention rate claimed by eMed holds true under the scrutiny of employer audits, it may set a new standard for how high-cost specialty drugs are managed in the workforce.
For now, the friction between Mark Cuban’s vision of transparent pharmacy and the marketing-heavy world of DTC telehealth remains a defining feature of the 2026 healthcare market. As obesity continues to be one of the most expensive conditions for the U.S. economy to manage, the collaboration between Cost Plus Drugs and eMed represents one of many strategic attempts to bring order—and lower prices—to a chaotic pharmaceutical landscape.
